Axitinib (Inlida) indication scope and therapeutic application of patients at different stages

Axitinib (Axitinib, trade name Inlyta/Inlyta) is an oral small molecule tyrosine kinase inhibitor (TKI), which mainly acts on VEGFR-1, VEGFR-2 and VEGFR-3 signaling pathways control tumor growth by inhibiting tumor angiogenesis. It was first approved for the treatment of advanced or metastatic renal cell carcinoma and is one of the most widely used anti-angiogenesis targeted drugs in clinical practice in the world.

Globally, axitinib is specifically approved for the treatment of patients with advanced renal cell carcinoma who have failed one prior systemic therapy, a typical "second-line treatment" regimen. In recent years, with the development of immune checkpoint inhibitors, combination regimens such as axitinib and pembrolizumab (Kdrug) have gradually expanded to first-line treatment and become one of the important options for patients with advanced or metastatic renal cancer. Some studies are also exploring its potential in other solid tumors, but it has not yet become a formal indication.

For early-stage kidney cancer, surgery is still the first choice, and axitinib is generally not used as adjuvant therapy. For patients who have entered the locally advanced or metastatic stage, if the initial first-line treatment (such as sunitinib or immune combination) fails, axitinib is often used as a second-line drug and can effectively prolong progression-free survival. For patients who are initially high-risk or have extensive metastases, axitinib combined with immunotherapy is increasingly recommended as the first-line standard treatment.

Generally speaking, the indications of axitinib are mainly concentrated in advanced and metastatic renal cell carcinoma It can be used as a single agent in the second line or in combination with immunological drugs in the first line. With the deepening of research, its applicable population is gradually expanding. For patients, rational selection of axitinib treatment timing and combination regimen, monitoring of side effects and standardized medication under the guidance of a doctor will help to obtain longer survival benefits.

Reference materials:https://www.drugs.com/